Barclays analyst Carter Gould raised the price target on Travere Therapeutics (NASDAQ: TVTX) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

TD Cowen Reiterates Buy Rating on Travere Therapeutics (TVTX)September 27, 2024 7:39 AM Travere Therapeutics (TVTX) PT Lowered to $19 at CitiSeptember 27, 2024 7:23 AM Travere Therapeutics (TVTX) PT Lowered to $17 at WedbushSeptember 27, 2024 6:48 AM Travere Therapeutics (TVTX) PT Lowered to $18 at H.C. WainwrightSeptember 27, 2024 6:43 AM Travere Therapeutics (TVTX) PT Lowered to $18 at BofA SecuritiesSeptember 27, 2024 5:59 AM After-hours movers: Costco, Scholastic Corp, Travere Therapeutics September 26, 2024 4:49 PM Form 8-K Travere Therapeutics, For: Sep 26September 26, 2024 4:03 PM Travere Therapeutics (TVTX) Announces Voluntary Pause of Enrollment in the Phase 3 HARMONY Study of PegtibatinaseSeptember 26, 2024 4:01 PM Travere Therapeutics Announces Voluntary Pause of Enrollment in the Phase 3 HARMONY Study of Pegtibatinase Related to Commercial Manufacturing Scale-UpSeptember 26, 2024 4:01 PM